Multiple sclerosis

Progentos Therapeutics Closes $65 Million Series A Financing to Advance Treatments for Multiple Sclerosis and Other Degenerative Diseases

Retrieved on: 
月曜日, 5月 20, 2024
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Patient, Survival, Entrepreneurship, Therapy, Remyelination, Disease, Census of agriculture, Multiple sclerosis, Alta Partners, Myelin, Disability, Axon

Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other demyelinating diseases, today announced its launch and the closing of a $65 million series A round.

Key Points: 
  • Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other demyelinating diseases, today announced its launch and the closing of a $65 million series A round.
  • This funding will enable Progentos to advance its MS program through human proof of concept studies and expand its pipeline in additional degenerative diseases.
  • Progentos is developing first-in-class small molecules designed to induce remyelination of axons affected by MS.
  • “We are truly excited to be part of Progentos’ journey towards delivering potentially disease-modifying drugs for diseases like multiple sclerosis, diseases with high unmet clinical needs.

Indapta Therapeutics Awarded $4.5 Million by CPRIT to Advance Clinical Development of its Allogenic Natural Killer Cell Therapy

Retrieved on: 
火曜日, 5月 21, 2024
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Genetic engineering, Interleukin, Patient, ADCC, Cytokine, NK, Clinical trial, Therapy, IND, Rituximab, Safety, Lymphoma, Multiple sclerosis, Cancer, Research, Multiple myeloma, Cytomegalovirus, CMV, Research institute, Cell, NKG2C

The $4.5 million grant will support Indapta’s ongoing clinical development of its lead product, IDP-023, for patients with advanced non-Hodgkin’s lymphoma and multiple myeloma.

Key Points: 
  • The $4.5 million grant will support Indapta’s ongoing clinical development of its lead product, IDP-023, for patients with advanced non-Hodgkin’s lymphoma and multiple myeloma.
  • “We greatly appreciate that CPRIT has recognized the promise of Indapta’s allogeneic g-NK cell therapy for the treatment of advanced cancer patients,” said Dr. Mark Frohlich, CEO of Indapta.
  • Indapta’s universal, allogeneic NK cell therapy platform consists of a potent subset of naturally occurring NK cells, known as “g minus” NK cells, or “g-NK” cells.
  • To generate IDP-023, Indapta preferentially expands g-NK cells from healthy donors, with low donor to donor variability.

Artificial Intelligence Tool Detects Sex-Related Differences in Brain Structure

Retrieved on: 
火曜日, 5月 14, 2024
NYU Langone Health, Bangladesh Technical Education Board, Doctor of Philosophy, Migraine, Machine learning, Scientific Reports, MRI, Male, Radiology, White matter, Multiple sclerosis, AI, Magnetic resonance imaging, Research, Artificial intelligence, Eye, NYU, Psychiatry, DSM-IV codes, Woman, Communication, Brain, Spectrum, Water, Female, Medical imaging

NEW YORK, May 14, 2024 /PRNewswire/ -- Artificial intelligence (AI) computer programs that process MRI results show differences in how the brains of men and women are organized at a cellular level, a new study shows. These variations were spotted in white matter, tissue primarily located in the human brain's innermost layer, which fosters communication between regions.

Key Points: 
  • Men and women are known to experience multiple sclerosis, autism spectrum disorder, migraines, and other brain issues at different rates and with varying symptoms.
  • A detailed understanding of how biological sex impacts the brain is therefore viewed as a way to improve diagnostic tools and treatments.
  • However, while brain size, shape, and weight have been explored, researchers have only a partial picture of the brain's layout at the cellular level.
  • According to the authors, the team next plans to explore the development of sex-related brain structure differences over time to better understand environmental, hormonal, and social factors that could play a role in these changes.

Keep Memory Alive Honors Blake Shelton and Hosts Star-Studded Lineup at 27th Annual Power of Love Gala

Retrieved on: 
月曜日, 5月 13, 2024
Diamond, Patient, DSM-IV codes, Mother, MGM Grand Garden Arena, Alzheimer's disease, The Power of Love, Myenteric plexus, MGM Grand, Neurodegenerative disease, Disease, Parkinson's disease, Cleveland Clinic, Sweet Caroline, Multiple sclerosis, Movement, Multiple system atrophy, Huntington's disease, Dementia, Pharmaceutical industry

LAS VEGAS, May 13, 2024 /PRNewswire/ -- Keep Memory Alive honored Blake Shelton at the 27th annual Power of Love® gala on Friday, May 10 at MGM Grand Garden Arena. An esteemed lineup of entertainers came together to celebrate the country music sensation including Gwen Stefani, Jay Allen, Colbie Caillat, Kristin Chenoweth, Andy Grammer, Mickey Guyton, Gary LeVox, Cassadee Pope and Jay Pharaoh.

Key Points: 
  • LAS VEGAS, May 13, 2024 /PRNewswire/ -- Keep Memory Alive honored Blake Shelton at the 27th annual Power of Love® gala on Friday, May 10 at MGM Grand Garden Arena.
  • Keep Memory Alive Co-founders Camille and Larry Ruvo welcomed the 1,500 guests, with Camille remarking, "Before there is a cure, there is a caregiver.
  • Even Shelton got into the action, bidding and winning a walk-on role in a Mark Wahlberg movie and later joking that he was a movie star.
  • For Power of Love updates or additional information, visit keepmemoryalive.org and follow on Instagram @ccnevadakma , Twitter @ccnevadakma and facebook.com/ccnevadakma .

Velocity National Provider Network Welcomes Local Infusion to Network, Making Affordable Infusion Therapy More Accessible

Retrieved on: 
月曜日, 5月 13, 2024
Partnership, Local, Patient, Gout, Practitioner, Infusion, Psoriasis, Multiple sclerosis, Crohn's disease, Velocity, Graves' ophthalmopathy, Rheumatoid arthritis, Inflammatory bowel disease

NASHVILLE, Tenn., May 13, 2024 /PRNewswire-PRWeb/ -- Velocity National Provider Network (VNPN) recently welcomed Local Infusion, an outpatient infusion therapy provider, to its care provider network as part of its ongoing work to expand access to top-tier healthcare services.

Key Points: 
  • Velocity National Provider Network (VNPN) members can receive in-network medication IV therapy at outpatient locations in New Hampshire, Maine, Connecticut and New Jersey
    NASHVILLE, Tenn., May 13, 2024 /PRNewswire-PRWeb/ -- Velocity National Provider Network (VNPN) recently welcomed Local Infusion, an outpatient infusion therapy provider, to its care provider network as part of its ongoing work to expand access to top-tier healthcare services.
  • Velocity National Provider Network (VNPN) proudly announces its partnership with Local Infusion, a leading healthcare provider in the Northeast.
  • "Velocity National Provider Network (VNPN) proudly announces its partnership with Local Infusion, a leading healthcare provider in the Northeast.
  • "We're excited to partner with Velocity National Provider Network as a national provider.

WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval

Retrieved on: 
金曜日, 5月 10, 2024
Ionization, Patient, Esophageal cancer, IIT, Toxicity, Patent, Nasopharyngeal carcinoma, NPC, Messenger, FDA, Cervical cancer, Malignancy, Breast cancer, Vaccine, Bone marrow, EB, Lipid, Multiple sclerosis, Research, Stomach, Lupus, Cancer, Lung cancer, Liver cancer

CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.

Key Points: 
  • CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.
  • This landmark achievement marks the world's first approval of an EB virus-related mRNA therapeutic cancer vaccine.
  • The FDA approval of WGc-043 represents a significant advance in cancer treatment, offering new hope to patients with advanced EB virus-related cancers.
  • EB virus is highly correlated with more than ten malignancies, including nasopharyngeal carcinoma (NPC), natural killer T-cell lymphoma (NKTL), gastric cancer, lung cancer, liver cancer, esophageal cancer, breast cancer, cervical cancer, and autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus.

WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval

Retrieved on: 
金曜日, 5月 10, 2024
Ionization, Patient, Esophageal cancer, IIT, Toxicity, Patent, Nasopharyngeal carcinoma, NPC, Messenger, FDA, Cervical cancer, Malignancy, Breast cancer, Vaccine, Bone marrow, EB, Lipid, Multiple sclerosis, Research, Stomach, Lupus, Cancer, Lung cancer, Multimedia, Liver cancer

CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.

Key Points: 
  • CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.
  • This landmark achievement marks the world's first approval of an EB virus-related mRNA therapeutic cancer vaccine.
  • The FDA approval of WGc-043 represents a significant advance in cancer treatment, offering new hope to patients with advanced EB virus-related cancers.
  • EB virus is highly correlated with more than ten malignancies, including nasopharyngeal carcinoma (NPC), natural killer T-cell lymphoma (NKTL), gastric cancer, lung cancer, liver cancer, esophageal cancer, breast cancer, cervical cancer, and autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus.

EQS-News: Immunic to Participate in Investor and Scientific Conferences in May

Retrieved on: 
金曜日, 5月 10, 2024
Assistant professor, AFL, Research, Cleveland Clinic, Serum, Coeliac disease, Psychiatry, Multiple sclerosis, Communication, DDW, SIRT6, Annual general meeting, CMSC, Biotechnology, Pharmaceutical industry

NEW YORK, May 6, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May:

Key Points: 
  • NEW YORK, May 6, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May:
    May 12-14 and 21-22: Bio€quity Europe 2024.
  • Jessica Breu, Vice President Investor Relations and Communications at Immunic, will attend and host one-on-one investor meetings at this conference taking place in San Sebastián, Spain and virtually.
  • To schedule a meeting, please use the Bio€quity conference portal or contact Jessica Breu at: [email protected] .
  • Presentation Title: Impact of Vidofludimus Calcium (VidoCa) on Serum Neurofilament Light Chain (NfL) Levels in Patients with Progressive Multiple Sclerosis: Interim Data from the CALLIPER Trial

Royalty Pharma Reports First Quarter 2024 Results

Retrieved on: 
木曜日, 5月 9, 2024
FDA, Ulcerative colitis, KarXT, Food, MorphoSys, European Commission, Marketing, New Drug Application, Cystic fibrosis, PDSS, PANSS, Tourette syndrome, Lupus, Docetaxel, Roche, Schizophrenia, Novartis, ADP, Pfizer, Incidence, Bristol Myers Squibb, Patient, Neurology, Acquisition, Sacituzumab govitecan, Olanzapine, Civil service commission, Multiple sclerosis, Positive, Vertex, Sanofi, Teva Pharmaceuticals, Astellas Pharma, European Medicines Agency, Lung cancer, Pharmaceutical industry

During 2024, Royalty Pharma announced new transactions of up to $619 million.

Key Points: 
  • During 2024, Royalty Pharma announced new transactions of up to $619 million.
  • In January 2024, Royalty Pharma acquired a royalty interest in ecopipam for an upfront payment of $49 million and up to $44 million in milestone payments contingent on the achievement of certain regulatory milestones.
  • In May 2024, Royalty Pharma announced a transaction to acquire royalties and milestones on frexalimab owned by ImmuNext for approximately $525 million in cash including estimated transaction costs.
  • Royalty Pharma has provided guidance for full year 2024, excluding transactions and borrowings announced after the date of this release, as follows:

Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

Retrieved on: 
木曜日, 5月 9, 2024
Type 1 diabetes, Lupus, Jefferies Group, Acquisition, Sclerosis, Multiple sclerosis, BLA, Immune system, Music

ImmuNext, a privately-held biotechnology company, is entitled to a royalty on net sales of frexalimab and milestones related to the achievement of regulatory and clinical events and commercial sales.

Key Points: 
  • ImmuNext, a privately-held biotechnology company, is entitled to a royalty on net sales of frexalimab and milestones related to the achievement of regulatory and clinical events and commercial sales.
  • Frexalimab is in three Phase 3 clinical studies for the treatment of multiple sclerosis (MS).
  • Sanofi stated that potential non-risk-adjusted peak sales for frexalimab may be greater than €5 billion (December 7, 2023 R&D Day).
  • Royalty Pharma estimates frexalimab, if approved, will generate royalties through 2041.